Pembrolizumab berahyaluronidase alfa vs Retifanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Pembrolizumab berahyaluronidase alfa · Keytruda Qlex
Marketed by Merck & Co.
NCT05722015 · Phase 3 · active, not recruiting
Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.
Next expected readout: December 2029 · NCT07190248 (registry estimate)
Reported efficacy
Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)
Result source: NCT05722015
Retifanlimab
Marketed by Incyte
NCT04205812 · Phase 3 · completed
Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).
Next expected readout: December 2027 · NCT07219576 (registry estimate)
Reported efficacy
Overall Survival (up to 39.1 months): Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) (met)
Result source: NCT04205812
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Pembrolizumab berahyaluronidase alfa | Retifanlimab |
|---|---|---|
| PFS, median | —Trial running · NCT05722015 | 7.7 vs 5.5+2.2 vs placeboNCT04205812 |
| OS, median | —Trial running · NCT05722015 | 18.1 vs 13.4+4.7 vs placeboNCT04205812 |
| ORR | 64.3% vs 18.2%vs PembrolizumabNCT06212752 | 51.7% vs 38.5%+13.2 vs placeboNCT04205812 |
| Duration of response, median | —Trial running · NCT05722015 | 12.7 vs 6.1+6.6 vs placeboNCT04205812 |
PFS, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Retifanlimab
- 7.7 vs 5.5+2.2 vs placeboNCT04205812
OS, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Retifanlimab
- 18.1 vs 13.4+4.7 vs placeboNCT04205812
ORR
- Pembrolizumab berahyaluronidase alfa
- 64.3% vs 18.2%vs PembrolizumabNCT06212752
- Retifanlimab
- 51.7% vs 38.5%+13.2 vs placeboNCT04205812
Duration of response, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Retifanlimab
- 12.7 vs 6.1+6.6 vs placeboNCT04205812
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Pembrolizumab berahyaluronidase alfa: 2 of 4 rows · Retifanlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pembrolizumab berahyaluronidase alfa | Retifanlimab |
|---|---|---|
| Dropout rate | n/a: no completion milestonea NCT05722015 · Phase 3 · combination show 1 more resultn/a: no completion milestone NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | 100%Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result—Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | —a NCT05722015 · Phase 3 · combination show 1 more result— NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | —Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result—Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 39%a NCT05722015 · Phase 3 · combination show 1 more result42.9% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | 40.6%Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result20.3%Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | show 1 more resultneutropenia 46.4% anaemia 42.9% constipation 39.3% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | anaemia 60.4% (placebo 56.8%) decreased appetite 22.6% (placebo 13.2%) neutrophil count decreased 21.6% (placebo 17.4%) NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more resultaspartate aminotransferase increased 23.7% (placebo 22.1%) anaemia 22% (placebo 56.8%) alanine aminotransferase increased 15.3% (placebo 23.7%) NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Retifanlimab
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab berahyaluronidase alfa's landscape · Retifanlimab's landscape